Literature DB >> 17471182

Population pharmacokinetic modelling of non-linear brain distribution of morphine: influence of active saturable influx and P-glycoprotein mediated efflux.

D Groenendaal1, J Freijer, D de Mik, M R Bouw, M Danhof, E C M de Lange.   

Abstract

BACKGROUND AND
PURPOSE: Biophase equilibration must be considered to gain insight into the mechanisms underlying the pharmacokinetic-pharmacodynamic (PK-PD) correlations of opioids. The objective was to characterise in a quantitative manner the non-linear distribution kinetics of morphine in brain. EXPERIMENTAL APPROACH: Male rats received a 10-min infusion of 4 mg kg(-1) of morphine, combined with a continuous infusion of the P-glycoprotein (Pgp) inhibitor GF120918 or vehicle, or 40 mg kg(-1) morphine alone. Unbound extracellular fluid (ECF) concentrations obtained by intracerebral microdialysis and total blood concentrations were analysed using a population modelling approach. KEY
RESULTS: Blood pharmacokinetics of morphine was best described with a three-compartment model and was not influenced by GF120918. Non-linear distribution kinetics in brain ECF was observed with increasing dose. A one compartment distribution model was developed, with separate expressions for passive diffusion, active saturable influx and active efflux by Pgp. The passive diffusion rate constant was 0.0014 min(-1). The active efflux rate constant decreased from 0.0195 min(-1) to 0.0113 min(-1) in the presence of GF120918. The active influx was insensitive to GF120918 and had a maximum transport (N(max)/V(ecf)) of 0.66 ng min(-1) ml(-1) and was saturated at low concentrations of morphine (C(50)=9.9 ng ml(-1)). CONCLUSIONS AND IMPLICATIONS: Brain distribution of morphine is determined by three factors: limited passive diffusion; active efflux, reduced by 42% by Pgp inhibition; low capacity active uptake. This implies blood concentration-dependency and sensitivity to drug-drug interactions. These factors should be taken into account in further investigations on PK-PD correlations of morphine.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17471182      PMCID: PMC2014001          DOI: 10.1038/sj.bjp.0707257

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  37 in total

1.  Role of morphine glucuronide metabolites in morphine dependence in the rat.

Authors:  A Salem; W Hope
Journal:  Pharmacol Biochem Behav       Date:  1997-08       Impact factor: 3.533

2.  Effect of GF120918, a potent P-glycoprotein inhibitor, on morphine pharmacokinetics and pharmacodynamics in the rat.

Authors:  S P Letrent; G M Pollack; K R Brouwer; K L Brouwer
Journal:  Pharm Res       Date:  1998-04       Impact factor: 4.200

3.  Methodological aspects of the use of a calibrator in in vivo microdialysis-further development of the retrodialysis method.

Authors:  M R Bouw; M Hammarlund-Udenaes
Journal:  Pharm Res       Date:  1998-11       Impact factor: 4.200

4.  Blood-brain barrier permeability to morphine-6-glucuronide is markedly reduced compared with morphine.

Authors:  D Wu; Y S Kang; U Bickel; W M Pardridge
Journal:  Drug Metab Dispos       Date:  1997-06       Impact factor: 3.922

5.  Active transport of fentanyl by the blood-brain barrier.

Authors:  T K Henthorn; Y Liu; M Mahapatro; K Y Ng
Journal:  J Pharmacol Exp Ther       Date:  1999-05       Impact factor: 4.030

6.  Concentration-effect relationships of morphine and morphine-6 beta-glucuronide in the rat.

Authors:  J T van Crugten; A A Somogyi; R L Nation; G Reynolds
Journal:  Clin Exp Pharmacol Physiol       Date:  1997-05       Impact factor: 2.557

7.  Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat.

Authors:  S P Letrent; G M Pollack; K R Brouwer; K L Brouwer
Journal:  Drug Metab Dispos       Date:  1999-07       Impact factor: 3.922

8.  Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats.

Authors:  E H Cox; J G Van Hemert; E J Tukker; M Danhof
Journal:  J Pharmacol Toxicol Methods       Date:  1997-10       Impact factor: 1.950

9.  P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs.

Authors:  A H Schinkel; E Wagenaar; C A Mol; L van Deemter
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

10.  Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.

Authors:  A H Schinkel; E Wagenaar; L van Deemter; C A Mol; P Borst
Journal:  J Clin Invest       Date:  1995-10       Impact factor: 14.808

View more
  22 in total

Review 1.  Transporter-Mediated Disposition of Opioids: Implications for Clinical Drug Interactions.

Authors:  Robert Gharavi; William Hedrich; Hongbing Wang; Hazem E Hassan
Journal:  Pharm Res       Date:  2015-05-14       Impact factor: 4.200

Review 2.  Opioid analgesics and P-glycoprotein efflux transporters: a potential systems-level contribution to analgesic tolerance.

Authors:  Susan L Mercer; Andrew Coop
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

3.  The 3D Brain Unit Network Model to Study Spatial Brain Drug Exposure under Healthy and Pathological Conditions.

Authors:  Esmée Vendel; Vivi Rottschäfer; Elizabeth C M de Lange
Journal:  Pharm Res       Date:  2020-07-09       Impact factor: 4.200

4.  Enhanced analgesic responses after preferential delivery of morphine and fentanyl to the olfactory epithelium in rats.

Authors:  John D Hoekman; Rodney J Y Ho
Journal:  Anesth Analg       Date:  2011-06-27       Impact factor: 5.108

Review 5.  [Drug interactions in pain therapy].

Authors:  K M J Syhr; B G Oertel; G Geisslinger
Journal:  Schmerz       Date:  2015-12       Impact factor: 1.107

Review 6.  Challenges of using in vitro data for modeling P-glycoprotein efflux in the blood-brain barrier.

Authors:  Noora Sjöstedt; Hanna Kortejärvi; Heidi Kidron; Kati-Sisko Vellonen; Arto Urtti; Marjo Yliperttula
Journal:  Pharm Res       Date:  2014-01       Impact factor: 4.200

7.  Pharmacokinetic modeling of non-linear brain distribution of fluvoxamine in the rat.

Authors:  Marian Geldof; Jan Freijer; Ludy van Beijsterveldt; Meindert Danhof
Journal:  Pharm Res       Date:  2007-08-21       Impact factor: 4.200

8.  Influence of biophase distribution and P-glycoprotein interaction on pharmacokinetic-pharmacodynamic modelling of the effects of morphine on the EEG.

Authors:  D Groenendaal; J Freijer; D de Mik; M R Bouw; M Danhof; E C M de Lange
Journal:  Br J Pharmacol       Date:  2007-04-30       Impact factor: 8.739

9.  The influence of age on the distribution of morphine and morphine-3-glucuronide across the blood-brain barrier in sheep.

Authors:  J Bengtsson; P Ederoth; D Ley; S Hansson; I Amer-Wåhlin; L Hellström-Westas; K Marsál; C-H Nordström; M Hammarlund-Udenaes
Journal:  Br J Pharmacol       Date:  2009-05-11       Impact factor: 8.739

10.  Impact of efflux transporters and of seizures on the pharmacokinetics of oxcarbazepine metabolite in the rat brain.

Authors:  R Clinckers; I Smolders; Y Michotte; G Ebinger; M Danhof; R A Voskuyl; O Della Pasqua
Journal:  Br J Pharmacol       Date:  2008-10-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.